马尔堡病毒医疗对策。

Marburg Virus Medical Countermeasures.

机构信息

Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC, USA.

出版信息

Methods Mol Biol. 2025;2877:25-43. doi: 10.1007/978-1-0716-4256-6_2.

DOI:10.1007/978-1-0716-4256-6_2

PMID:39585611

Abstract

Among the Filoviridae, Marburg virus (MARV) is a biological threat for which no licensed vaccines or therapeutics are currently available. In contrast, we have licensed products for Ebola virus (EBOV), another member of the Filoviridae family. The availability of licensed medical countermeasures (MCMs) for EBOV provides an opportunity to test a key objective of many pandemic preparedness plans, which is to apply some of the same technological approaches demonstrated to be successful for one agent, EBOV, to a second agent, MARV. This chapter will discuss (1) lessons learned from EBOV outbreak responses and MCM development that are applicable to MARV MCM development, (2) the likely concept of operations for using vaccines and therapeutics against MARV, and (3) target product profiles based on the concept of operations. Finally, we will discuss the current status of the MCM pipeline for MARV and next steps to advance these countermeasures to licensure.

摘要

在丝状病毒科中，马尔堡病毒（MARV）是一种生物威胁，目前尚无许可的疫苗或疗法。相比之下，我们有针对埃博拉病毒（EBOV）的许可产品，EBOV 也是丝状病毒科的一个成员。EBOV 许可医疗对策（MCM）的出现为许多大流行准备计划的一个关键目标提供了一个检验机会，该目标是将针对一种病原体（EBOV）成功应用的相同技术方法应用于第二种病原体（MARV）。本章将讨论（1）从 EBOV 暴发应对和 MCM 开发中吸取的适用于 MARV MCM 开发的经验教训，（2）针对 MARV 使用疫苗和疗法的可能操作概念，以及（3）基于操作概念的目标产品概况。最后，我们将讨论 MARV 的 MCM 管道的现状以及推进这些对策获得许可的下一步措施。